Triple Therapy Versus Dual Antiplatelet Therapy for Patients with Atrial Fibrillation and Acute Coronary Syndromes: A Systematic Literature Review

By  

Current Cardiology Reviews, Vol. 13, Iss. 4, 2017-10 ,pp. : 325-333

Bentham Science Publishers

Access to resources Recommend Favorite

Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial

By Geller Bram   Mega Jessica   Morrow David   Guo Jianping   Hoffman Elaine   Gibson C.   Ruff Christian  

Journal of Thrombosis and Thrombolysis, Vol. 37, Iss. 3, 2014-04 ,pp. : 310-316

Springer Publishing Company

Access to resources Recommend Favorite

Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?

By  

Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol. 12, Iss. 1, 2014-04 ,pp. : 14-20

Bentham Science Publishers

Access to resources Recommend Favorite

Prasugrel: A Novel Antiplatelet Therapy for Acute Coronary Syndromes

By  

Recent Patents on Cardiovascular Drug Discovery, Vol. 4, Iss. 3, 2009-11 ,pp. : 192-202

Bentham Science Publishers

Access to resources Recommend Favorite

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 5, Iss. 2, 2016-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite